Fred Hutch Cancer Center | Strategic Alliance Partners

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

Elena Gabriela Chiorean, MD, discusses the role of genetic testing in pancreatic cancer.

Julie Gralow, MD, discusses exciting research in HER2-positive breast cancer.

Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.

Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

Christina Baik, MD, MPH, highlights the evolving role of EGFR inhibition in the NSCLC space.

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Heather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

William R. Gwin III, MD, discusses the ongoing trial examining this novel combination and provided insight into the next steps for this research.

William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

This OncLive webinar will uncover the latest treatments in myelofibrosis by Bart Scott, MD. Join us on Tuesday, April 28, 2020 or Thursday, April 30, 2020 at 5 PM or 8 PM EDT.

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.

Jerald P. Radich, MD, discusses the growing importance of MRD assessment in the treatment paradigm for patients with hematologic malignancies.

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Petros Grivas, MD, PhD, discusses the role of targeted therapy in prostate cancer.

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

Andrew J. Cowan, MD, discusses efficacy and safety of BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Julie R. Gralow, MD, discusses the emergence of biosimilars in the United States and globally.

Julie R. Gralow, MD, discusses the science of biosimilars and their implementation in breast cancer.

We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.

Petros Grivas, MD, discusses searching for biomarkers in patients with urothelial cancer to indicate response to pembrolizumab in the KEYNOTE-052 trial.